NeueHealth, Inc. (NYSE:NEUE) has reported that Tomas Orozco, the company\'s Executive Vice President of Consumer Care, sold a total of 822 shares of common stock on March 18, 2024. According to the filing, the shares were sold at a weighted average price of $7.27, with transactions occurring at various prices ranging from $7.16 to $7.39 per share. The total value of the shares sold by Orozco is over $5,900.
The sale of shares by Orozco was related to tax withholding obligations that arose from the vesting of restricted stock units. The executive\'s transactions were not discretionary and were required to cover the tax liability associated with the vesting of these equity awards.
Following the sale, Orozco continues to hold 5,092 shares of NeueHealth, Inc. The transaction was reported in a regulatory filing with the Securities and Exchange Commission, which provides transparency into the trading activities of the company\'s insiders.
NeueHealth, Inc., previously known as Bright Health Group Inc (NYSE:NEUE)., operates within the hospital and medical service plans industry, and is incorporated in Delaware. The company\'s business address is located in Doral, Florida.
Investors often monitor insider transactions as they can provide insights into the confidence that company executives and directors have in the firm\'s future prospects. However, it\'s important to note that there can be various reasons for insiders to sell shares, and such transactions do not always indicate a change in the company\'s outlook.
The stock transaction was signed on behalf of Tomas Orozco by Eric Halverson, as Attorney-in-Fact, on March 20, 2024.
Pro Insights
As investors digest the news of Tomas Orozco\'s recent stock sale from NeueHealth, Inc. (NYSE:NEUE), it\'s crucial to consider the company\'s financial health and market performance. According to Pro data, NeueHealth has a market capitalization of 55.99 million USD, which positions it as a smaller player in the hospital and medical service plans industry. Despite the challenges reflected in the recent stock sale, the company\'s stock has experienced a strong return over the last three months, with a price total return of 34.65%.
Pro Tips reveal that analysts are predicting a sales decline in the current year, which could impact the company\'s performance. Additionally, the stock is known for its high price volatility, which may contribute to the recent insider sale being part of a strategy to manage personal investment risk. With a P/E Ratio (Adjusted) for the last twelve months as of Q4 2023 at -0.14, it\'s evident that the market has concerns about the company\'s profitability.
For investors looking for a more comprehensive analysis, Pro offers additional insights, including the fact that NeueHealth does not pay a dividend to shareholders, which may influence investment decisions for those seeking regular income. Furthermore, the company has not been profitable over the last twelve months, and its short-term obligations exceed its liquid assets, indicating potential liquidity issues.
To access more detailed analyses and tips that could guide investment decisions in NeueHealth, visit Pro. And remember, by using the coupon code PRONEWS24, you can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 11 more Pro Tips available that could provide further value to your research on NEUE.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.